. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Coumafene"@en . . . "81-81-2"@en . . . . . . . . . "* 0.065 +/- 0.025 mL/min/kg [CYP2C9 Genotype *1/*1] * 0.041 +/- 0.021 [CYP2C9 Genotype *1/*2 or *1/*3] * 0.020 +/- 0.011 [CYP2C9 Genotype *2/*2, *2/*3, or *3/*3]"@en . . . . . "Nasri W. Badran, \"Microcrystalline 3-(alpha-acetonylbenzyl)-4-hydroxycoumarin (warfarin) and methods of making.\" U.S. Patent US4113744, issued April, 1960."@en . . "Limit garlic, ginger, gingko, and horse chestnut."@en . . . . . . . . . . "Warfarin inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots."@en . . "* 0.14 L/kg"@en . . " "@en . . . . . . . "# Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):204S-233S. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15383473 # Whitlon DS, Sadowski JA, Suttie JW: Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978 Apr 18;17(8):1371-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/646989 # Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase. Nature. 2004 Feb 5;427(6974):541-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14765195 # Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004 Feb 5;427(6974):537-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14765194 # Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003 May 7;41(9):1633-52. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12742309 # Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS: Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005 May 23;165(10):1095-106. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15911722 # Macina, Orest T.; Schardein, James L. (2007). \"Warfarin\". Human Developmental Toxicants. Boca Raton: CRC Taylor & Francis. pp. 193\u20134 # Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):160S-198S. doi: 10.1378/chest.08-0670. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18574265 # Freedman MD: Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1564123 # Loftus, Christopher M. (1995). \"Fetal toxicity of common neurosurgical drugs\". Neurosurgical Aspects of Pregnancy. Park Ridge, Ill: American Association of Neurological Surgeons. pp. 11\u20133."@en . . . . . . . . . . . . . . . . . "99% bound primarily to albumin"@en . . . . . . . . "For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . "R-warfarin t_1/2=37-89 hours; S-warfarin t_1/2=21-43 hours. "@en . . . . "Avoid St. John's Wort."@en . "LD₅₀=374 (orally in mice)"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Zoocoumarin"@en . . . . . . . . "Consult your doctor before ingesting large amounts of dietary Vitamin K (e.g. from green leafy vegetables)."@en . . . . "The elimination of warfarin is almost entirely by metabolism. Very little warfarin is excreted unchanged in urine. The metabolites are principally excreted into the urine; and to a lesser extent into the bile."@en . . . . . . . . . . . "Warfarin"@en . "Rapidly absorbed following oral administration with considerable interindividual variations. Also absorbed percutaneously. "@en . . "Humans and other mammals"@en . "approved"@en . . "4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin"@en . . " "@en . . . . . . "Avoid alcohol."@en . "Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. "@en . "Avoid drastic changes in dietary habit."@en . . . .